Tags Posts tagged with "Cannabis"

Cannabis

Medical Marijuana Shows Parkinson’s Patient Some Relief

Ian Frizell, age 55, was diagnosed with Parkinson’ disease in 2011. He has suffered from symptoms since 1995, which continually got worse over time. Ian has filmed a video to display what a significant difference a small amount of medical marijuana makes to his tremors. In the clip, he states that he recently underwent deep brain stimulation surgery, a medical implant that helps hide the effects of Parkinson’s. He switches the DBS device off to show the seriousness of his tremors.

 


Click Here To View Full Article


 

Research Reveals Some Of Marijuana’s Health Effects

 

It may essentially help some people sleep and ease chronic pain, but it is also possible to heighten the danger of triggering a heart attack or develop schizophrenia. A Federal advisory panel came to those those conclusions about cannabis in a recent report.

The analysts also called for a…


Click Here To View Full Article


 

Vitality Biopharma (VBIO)

 

Vitality Biopharma (VBIO) has been in our spotlight for the better part of the last few weeks and we’ve seen this cannabis biotech deliver real potential for gains. What started out as a $0.98 alert ended up turning into a $4.24 bull. Even after pulling into $1.93, VBIO managed several clear bounces. This will be something we’ll be continuing to monitor into the later half of the month as well. If you haven’t taken a look at this company yet, check out our full report via the link below.


Click Here To View Full VBIO Report


 

 

Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 1049

Vitality Biopharma to Present at Biotech Showcase 2017

LOS ANGELES, CA–(Marketwired – Jan 9, 2017) – Vitality Biopharma, Inc. ( OTCQB : VBIO ) (“Vitality Biopharma,” “Vitality,” or the “Company”) a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced that it will present at the Ninth Annual Biotech Showcase 2017 Conference, on January 11, at the Hilton San Francisco Union Square.

Company CEO Robert Brooke will provide a 30-minute overview of Vitality Biopharma’s business during his presentation and will be available to participate in one-on-one meetings with registered attendees.

Event: Biotech Showcase Conference
Date: Wednesday, January 11, 2017
Time: 8:00 a.m. PT
Track: Room 8 (Ballroom Level)
Location: Hilton San Francisco Union Square, San Francisco, CA

Investors and other interested parties will be able to access a copy of the presentation by visiting the investors section of the Vitality Biopharma website at http://vitality.bio/investors/presentation.

About Biotech Showcase 2017
Biotech Showcase™ is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry’s largest annual healthcare investor conferences.

About Vitality Biopharma ( OTCQB : VBIO )
Vitality Biopharma is dedicated to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. For more information, visit: www.vitality.bio. Follow us on Facebook, Twitter and LinkedIn.

Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27(a) of the United States Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

0 571

 Vitality Biopharma (VBIO) Set To Continue Trend Into “BigWeek” For Biotech?

 

Today’s the day that kicks off JPMorgan’s annual health-care conference; coined the industry’s biggest gathering. As we said last week, many in the space have said that this conference has proven to be a catalyst for the sector overall. So why mention this, as a marijuana focused outlet? Our most recent featured company Vitality Biopharma (VBIO) finds itself at the cross-roads where cannabis meets biotech. Not only did VBIO see a green close on Friday after 3 consecutive days of consolidation but it’s also heading into the week where biotech will seemingly be in the spotlight for many investors.

“Biotech has historically outperformed the broader market during The J.P. Morgan Healthcare Conference,” biotech analysts at the firm wrote in a note to clients ahead of the event.

And we aren’t the only ones who could be seeing the potential “writing on the wall.” One of the presenters at the conference has even said, “…there’s a growing interest in medical cannabis among traditional health care institutions. This is a growing part of what is becoming mainstream health care.” As we said last week, even though we focus specifically on marijuana stocks, the biotech aspect of VBIO could be something to pay attention to heading into this week, considering the historic impact that the JPM conference (starts today) has had in the past for companies that have a stake in the space.


Click Here To View Full VBIO Report


 

Dive Into The Steady Growing Cannabis Market

 

Co-founder of Vapium, a Canadian marijuana vape-maker states, “If you have a passion, any passion, we need advocates and allies. If you’re a baker, we need bakers. If you’re a lawyer, we need lawyers. Anyone who has empathy for people who need weed, and is driven, is welcome in the marijuana industry. There’s still so much opportunity.” The cannabis industry seems like it’s ready to take off. In 2016, the legal weed market in North America Generated $6.7 billion, up 30% from 2015, Arcview Market Research announced.

Washington DC has passed laws allowing…


Click Here To View Full Article


 

Lets Take a Deeper Look at California’s Most Popular Crop

 

California was already known as a major cannabis producer well before it legalized recreational marijuana in November. The state’s marijuana crop is not only the most profitable product in the nation’s biggest agricultural state, it is much farther ahead of the next most popular crop, according to the Orange County Register. California’s mild climate made Central Valley the breadbasket of the world at one time and provided the United States with fruits and vegetables that grew in very few other places. However, the biggest crop in California’s assorted bounty is currently marijuana.


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 2091

 

What To Watch With Vitality Biopharma ($VBIO)

 

Vitality Biopharma (VBIO) is staying at the top of our list this week. We’ve witnessed first-hand how strong of a run that this has had and continues to have. Over the last few days we’ve seen VBIO hold a tend above $2.50, where last week it saw a trend in the higher $1 range. In fact since last week, VBIO is trending more than 30% higher than those previous lows. Keep in mind that within the last few weeks VBIO has hit highs of $4.23 so as many of you have already witnessed, this has been capable of dynamic breakouts over shorter periods of time.

This is all happening as the company continues to make progress with their novel therapies. has been going by route of prodrugs. Their unique approach targets CB2 receptors and can be taken orally to directly target specific tissues or organs. Right now, the company is working to create therapies for Crohn’s disease patients and those who suffer from inflammatory bowel disease. VBIO has filed intellectual property applications and is seeking worldwide patent protection through 2035, with strong composition of matter claims for its prodrugs.

In fact, the company’s novel use of certain developmental therapies have been shown to be nearly 10 times as potent as morphine for neuropathic pain relief. And if you remember, they’ve also just received the Drug Enforcement Administration’s approval for its pharma development facility…something that not many of its competitors (if any) can say right now especially in the current climate. Looking for more on VBIO?

 


Click Here To View Full VBIO Report



Things To Expect After Medical Cannabis Is Legal In Florida

Dr. Joseph Dorn was the medical director of Surterra Therapeutics, which is one of six distributing locations that are licensed to dispense medical marijuana in the state of Florida. The constitutional amendment allows higher-strength cannabis to be used for a broader range of medical conditions. However, the true measure of what the amendment means won’t be seen immediately until a new set of rules are carried out by the State’s Legislature.


Click Here To View Full Article


 

#ICYMI: Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

 

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.

 


Click Here To View Full Article


Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 565

 

Vitality Biopharma ($VBIO)’s 3-Day Rally Set To Continue?

Vitality Biopharma (VBIO) saw a very strong run during most of December. When we first began to pick up coverage it was sitting around $0.98 and during the course of the weeks to follow, we watched as VBIO ran to highs of $4.23. Despite the fact that many thought the excitement was over when VBIO pulled back, we’ve now seen it breakout once again. In fact since bottoming at $1.93 last week, VBIO has maintained a 3 day run that has taken it back to highs of $3.22 yesterday; a 67% rebound.

We said it late last year and the sentiment continues to hold up so far in 2017: Canna-biotech companies have begun to catch much more attention; biotech over all has begun to see an increase in activity following President Elect Trump coming into the spotlight. In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%. This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

Vitality’s preclinical studies for its proprietary prodrugs of CBD and THC were recetnly reviewed and approved by the U.S. FDA. So, if is your first time seeing VBIO, we’ve got a full report you can access before the opening bell today.

 


Click Here To View Full VBIO Report



The Hero of HOLLYWEED

 

In case you missed it this New Years the citizens and tourists got a wonderful welcome when they looked up at Mount Lee in HollyWood, or should we say “HOLLYWEED!” The Iconic Hollywood sign was given a hilarious, yet impactful redesign given that the state of California now has recreational marijuana after a November 8th vote in favor of the law change by its illustrious citizens.

 


Click Here To View Full Article


 

Senator Warren Is Working on Getting Banks To Do Business With The Marijuana Industry

As marijuana shops start to sprout and grow within states that have legalized the drug, they face a critical stumbling road block – lack of access to the kind of routine banking services other businesses take for granted. U.S. Sen. Elizabeth Warren, a Massachusetts Democrat, is making a solid attempt at making an effort to ensure vendors working with legal marijuana businesses, from chemists who test marijuana for harmful substances to firms that provide security, don’t have their banking services taken away.


Click Here To View Full Article



Pursuant to an agreement between MAPH and a non affiliate third party, we were hired for a period of 30 days to publicly disseminate information about (VBIO) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VBIO) which we purchased in the open market. We plan to sell “ZERO” shares of (VBIO) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of ( VBIO) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

0 16285

Today is the final trading day of the year will definitely be one that investors will always remember. The market remains in the positive as companies are better positioned for success. From the advance of the Canadian marijuana industry to election of Donald Trump, there will be a lot for investors to watch next year. We would like to highlight some themes anticipated to play out over 2017.

Consolidation

One of the brightest spots of the marijuana industry in 2016 was the Canadian licensed medical marijuana producer sub-sector. In early December, Mettrum Health (MT.V)(MQTRF) and Canopy Growth (CGC.TO)(TWMJF) announced an agreement where Canopy Growth will gain all of the outstanding shares of Mettrum.

Keep your eyes on the marijuana industry as it is expected to see more deals like this over the next year. The possibility for increase consolidation makes these companies attractive investment opportunities: Aphiria (APH.V)(APHQF), Supreme (SL.V)(SPRWF), OrganiGram (OGI.V)(ORGMF), Emblem Corporation (EMC.V), and Aurora Cannabis (ACB.V)(ACBFF).

Transformation

The biotech sector will be one of the greatest recipients of the legal marijuana movement and recent sector weakness has created opportunities for investors.
GW Pharmaceuticals (GWPH) reported its second Stage Three Clinical trial in September for its Epidiolex product for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS). We continue to view GWPH as one of the top marijuana investments due to its capability to convert the cannabis industry through the development of treatments for sickness’ that don’t currently have an approved regimen.

Execution

From the financial structure, investors need to conduct with earnestness. We suggest incorporating some guidelines into your investment blueprint.

To end 2016, we want to highlight some of the stocks investors should watch during next year: Emblem Corporation (EMC.V)(EMMBF), Zoned Properties (ZDPY), Aphria (APHQF), Kush Bottles (KSHB), American Cannabis (AMMJ), Aurora (ACBFF), Reliq Healthcare (RQHTF), Zynerba Pharmaceuticals (ZYNE), OrganiGram (OG.V)(ORGMF), Arcturus Grothstar Tech (AGSTF), MassRoots (MSRT), VPR Brands (VPRB), CV Sciences (CVSI), mCig (MCIG), Canopy Growth (TWMJF)(CGC.TO), Medicine Man Tech (MDCL), GW Pharmaceuticals (GWPH), Lexaria (LXRP), Canabo Medical (CMM.V)(CAMDF), Mettrum Health (MT.V), and VinergyRes (VIN.CN).

    0 1479

    Vitality Biopharma, Inc. (VBIO):

    Technical Update

     

    We’re heading into a new week and continue to keep Vitality Biopharma Inc. (VBIO) in our main spotlight. Canna-biotech has been something we’ve reported on in detail and VBIO is heavily involved within the space.

    Over the last few weeks, we’ve highlighted several key points about the company and the potential of the market but what could be even more exciting is the technical pattern that could be developing:

    There are a lot of technical indicators flashing on this chart that could be catalysts for a continuation trend as VBIO keeps pressing to break upper resistance levels on its chart.

    Granted that since we’ve begun covering the company, VBIO has managed to climb roughly 50%. Even with this being the case, there has been a noticeable level of resistance around the $1.45-$1.47 area on the chart to where there could be a potential short squeeze scenario in the making.

    VBIO has seen a significant jump in momentum over the last few weeks. Since we alerted it, we’ve now seen our newest cannabis biotech feature rally to highs of $1.47 so far. Keep in mind that we picked up coverage on this company just as it was hitting a bottom during a pull-back period. Prior to this VBIO was trading as high as $1.84 during more recent months & as high as $2.25 during the summer. So if this is your first time seeing VBIO in brief, check out the full report here:

    The Future Of Cannabis Biotech:
    Connecting The Dots

    As always, if you have any questions for us, don’t hesitate to reach out. We try to respond as quickly as possible to everyone’s request and if you’re new to trading, don’t forget to check out our intro videos HERE.


     


     

     

     





     

    We receive roughly 50-100 emails per day, 7 days per week 365 days per year asking the following;

    How do I get started trading stocks specifically Marijuana Stocks?

    In order to buy any kind of stock you need a brokerage account. You need to know how to fund that account and eventually how to properly place buy and sell orders and last but not lease how to read and understand level 2. We found a series of short videos on YouTube that we posted on our page that will help you get up and trading quickly so you can take advantage of the HOT Marijuana Stocks.

    Learn how to get started trading stocks right here right now

    What Marijuana Stocks are worth Buying?

    We cover all publicly traded marijuana stocks on our website. From time to time we identify those that stand apart from the crowd, the cream of the crop. When we identify these companies, we begin taking steps to alert them to YOU our audience.

    Speaking of MJ Stocks Worth Buying…

    We believe investors need to focus their attention on the cannabis biotech sector RIGHT NOW. Recent political shifts are setting up a “perfect storm” scenario for the cannabis biotech sector. One biotech fund manager even said he thinks the entire sector is about to double. For this reason, we will be profiling a new cannabis biotech company that we will be sticking with long term. PLEASE read that AGAIN, we said LONG TERM. In other words, this will NOT be a “Day Trade.” Not a “quick flip”. For those that don’t know Biotech & Marijuana are two of the HOTTEST sectors right now and will ONLY continue to get BIGGER and BIGGER as technology & law/ regulations advances.

    Before We Alert this New, Company You Need to do 2 Things;

    Again, PLEASE read, Why Cannabis Biotech Needs to be in Your Portfolio Right Now Here

    7 5296

    The biotech sector may be one of the biggest beneficiaries of the legal cannabis movement.

    In previous articles, we have been quite vocal about our bullish stance on the cannabis biotech sector. In the current US markets, we believe the greatest opportunity lies in biotech and the pharmaceutical production of cannabinoid and cannabis related drug treatments. And recent political shifts may have just created a perfect storm for cannabis biotech investors. Right now could be your greatest opportunity to consider adding cannabis biotech to your portfolio. And we aren’t the only ones who think so.

    Todd Hagopian, manager of a biotech fund at Marketocracy, believes the biotech sector will benefit most from a Donald Trump Presidency. Todd is one of the most successful biotech investors in the market today. His returns have averaged 26.03% since starting his fund in 2011, which compares nicely to the S&P 500’s 11.58% return over the same period. Over the last five and three year periods, Todd Hagopian did better than the top U.S. Equity fund managers.

    But why are we so bullish on cannabis biotech?

    For over a year, analysts have been anticipating and factoring in a Hillary Clinton victory that sent the ishares NASDAQ Biotechnology ETF (IBB) plummeting 23% from 9/21/15 through Election Day this November. Why? Clinton was very vocal about her desire to slash what she believed to be excessive profits in the biotech industry. This would force drug companies to lower prices that would tighten margins and decrease net profit. If Clinton won the election, there were concerns that she would flip the Senate and/or House of Representatives to Democratic control. This would have allowed her to take action on the pricing practices of the biotech sector.

    But with the White House and Congress now in Republican control, the biotech sector is set up for an extraordinary comeback. In fact, it has already begun. The IBB is up about 10% since Election Day. With Trump taking the White House, biotech investors could be in for one heck of a ride as this could be just the beginning of a move that could see the biotech sector double.

    In an interview with Ken Kam of Forbes, Todd Hagopian said, “After underperforming the S&P 500 by over 30% in the past 14 months, there is plenty of room for this sector to run. In fact, the S&P 500 Biotechs are trading at a Forward P/E of just 22.4% vs. Consumer Staples who are trading at a Forward P/E of 17.2%.  This is pretty remarkable, considering that the same group of Biotech companies have a short term earnings growth rate of 17.3%, versus the Consumer Staple companies who are projected to grow at just 8.0%. Basically, this data would seem to suggest that either there is a huge bubble in Consumer Staples stocks, or the Biotechnology market is about to double.”

    This is the perfect storm for cannabis biotech investors. Not only is the overall biotech industry expected to experience a massive bull run, but cannabis legalization is quickly spreading across the US. The November Election Day was an enormous victory for the cannabis industry. There are now 8 states that allow the recreational use of marijuana and another 21 that allow its medical use. We could be looking at a golden opportunity for cannabis biotech investors.

    In his interview with Forbes, Hagopian went on to name a few other catalysts that biotech investors seem to have in their favor:

    1. The Obamacare fight needs to stay away from pricing. The odds of a Republican House and Senate trying to pass a law regulating drug prices, and have it signed by a Republican President seems slim to none.
    2. The Supreme Court needs to stay conservative. Donald Trump has already promised to nominate conservative judges to the court. The Supreme Court will likely stay 5-4, or even 6-3, in favor of conservative views.
    3. M&A activity needs to restart. The low valuations seen in the biotech sector after the Clinton selloff mentioned earlier in this article has sparked a ton of M&A rumors in the biotech sector. The Clinton biotech scare not only provided great opportunity for individual investors but also for large biotech titans to swallow up smaller companies with promising intellectual property and clinical data from early drug trials. We have already seen recent M&A activity in the cannabis sector with Canopy Growth Corp., Canada’s largest marijuana company, agreeing to buy competitor Mettrum Health Corp. for $8.42 a share.

    The current environments of the overall biotech sector and marijuana industry have created an exciting time for cannabis biotech investors. Several catalysts are aligning for what could be a booming 2017 for the entire space. In addition, many companies are expected to announce FDA clinical and pre-clinical trial data soon. Favorable results will be a catalyst to send individual stocks and the overall cannabis biotech sector considerably higher.

    If you haven’t done so already, it’s time to consider adding cannabis biotech to your portfolio, Now!

      0 1057

      The volume of cannabis stocks listed on the Nasdaq have spiked ahead of the election with some stocks rising as much as 12% on Monday as voters decide tomorrow whether five states will allow recreational use of marijuana while four other states could approve medical use.

      Interest in cannabis-related stocks has risen from micro cap to Nasdaq-listed equities, said Jason Spatafora, co-founder of Marijuanastocks.com and a Miami-based trader and investor known as @WolfofWeedST on Twitter. The market is predicting that voters in California and Nevada will approve legislation for recreational use and anticipates that Florida will legalize medical use.

      “Should more states adopt laws to legalize either recreational or medicine use of marijuana, we can see a continued run going into the new year,” he said.

      -Continue Reading, Here-

      Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

      We are your #1 source for all things Marijuana Stocks, Subscribe Below!

      Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
      Ad Placements